Tibulizumab

Tibulizumab (LY 3090106) is a tetravalent bispecific monoclonal antibody targeting B-cell activating factor (BAFF) and IL-17A with Kd values of 60 pM and 14 pM, respectively. Tibulizumab can be used for autoimmune disease research[1].

Product Specifications

CAS Number

[1849636-24-3]

Product Name Alternative

LY 3090106

UNSPSC

12352203

Target

Interleukin Related; TNF Receptor

Type

Inhibitory Antibodies

Related Pathways

Apoptosis; Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/tibulizumab.html

Purity

98.86

Solubility

10 mM in DMSO

Smiles

[Tibulizumab]

Molecular Weight

(201.43 kDa)

References & Citations

[1]Robert J Benschop, et al. Development of tibulizumab, a tetravalent bispecific antibody targeting BAFF and IL-17A for the treatment of autoimmune disease. MAbs. 2019 Aug/Sep;11 (6) :1175-1190.